Christopher Granger, MD: Patient Tolerability of Anticoagulants
AUGUST 27, 2016
Christopher Granger, MD, Duke University Medical Center also spoke at the European Society of Cardiology Congress 2016 about the issues surrounding patients' tolerability of anticoagulants and other drugs. "About half of peopel who start on a drug proven to be effective stop it within a year, because of intolerance to the drug, ineffectiveness, or sometimes because of lack of adherence - cause as human beings we may not be so good at reliablytaking things," Granger explained. So, at ESC 2016, Granger and team were reporting that apixaban was better tolerated than warfarin.